Immunological effects of CD19.CAR-T cell therapy in systemic sclerosis: an extended case study
Maren Claus, Merle Freitag, Meike Ewald, Lea Rodon, Franca Deicher, Carsten Watzl, Philipp Kolb, Hanns-Martin Lorenz, Michael Schmitt, Wolfgang Merkt · 2024
Read Immunological effects of CD19.CAR-T cell therapy in systemic sclerosis: an extended case study by Maren Claus, Merle Freitag, Meike Ewald, Lea Rodon, Franca Deicher, Carsten Watzl, Philipp Kolb, Hanns-Martin Lorenz, Michael Schmitt, Wolfgang Merkt (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11639114.txt.
Description
Maren Claus and co-authors followed one systemic sclerosis patient's immune system for eighteen months after CAR-T cell therapy, in a 2024 case study. The treatment, borrowed from cancer care, wipes out the B cells behind harmful autoantibodies. This patient's clinical improvement was already known. The team asked what happened to the innate immune side, using a twenty-nine-color cell-sorting panel on blood samples over time.
Natural killer cells, front-line innate fighters, shifted toward a younger, calmer, less worn profile. Meanwhile the patient's serum lost its power to form antibody complexes that switch those killer cells on. Sera from other sclerosis patients confirmed the mechanism: the complexes activate the cells in proportion to dose. The authors propose a chain: clearing autoimmunity cools the innate system too, which may deepen the therapy's benefit.
Catalog record
| CREATOR | Maren Claus, Merle Freitag, Meike Ewald, Lea Rodon, Franca Deicher, Carsten Watzl, Philipp Kolb, Hanns-Martin Lorenz, Michael Schmitt, Wolfgang Merkt |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |